A chemically defined production process for highly attenuated poxviruses.
Highly attenuated poxviruses are promising vectors for protective and therapeutic vaccines. These vectors do not replicate in human cells and can therefore be safely given even to immunocompromised recipients. They can accommodate very large inserts and provide strong stimulation of the immune system against the vectored antigen. Disadvantages include that very high numbers of infectious units are required per dose for full efficacy. Because they are difficult to produce, improved cellular substrates and processes are urgently needed to facilitate programs intended to reach a large number of vaccinees. We have developed a fully scalable and very efficient chemically-defined production process for modified vaccinia Ankara (MVA), canarypox (CNPV, strain ALVAC) and fowlpox viruses (FPV) based on a continuous cell line.
ProBioGen AG, Goethestr. 54, 13086 Berlin, Germany. ingo.jordan@probiogen.de
Ingo
I
Jordan
Stefan
S
Northoff
Michael
M
Thiele
Stefan
S
Hartmann
Deborah
D
Horn
Kristin
K
Höwing
Holger
H
Bernhardt
Stefanie
S
Oehmke
Henning
H
von Horsten
Dierk
D
Rebeski
Lars
L
Hinrichsen
Vladimir
V
Zelnik
Wiebke
W
Mueller
Volker
V
Sandig
D000818:Animals; D019149:Bioreactors; D016466:CHO Cells; D028121:Canarypox virus / Q000235:genetics / Q000276:immunology; D002460:Cell Line; D049109:Cell Proliferation; D006224:Cricetinae; D003412:Cricetulus; D005587:Fowlpox virus / Q000235:genetics / Q000276:immunology; D005822:Genetic Vectors / Q000235:genetics* / Q000276:immunology; D006801:Humans; D011212:Poxviridae / Q000235:genetics* / Q000276:immunology; D014613:Vaccines, Attenuated / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology; D014779:Virus Replication / Q000235:genetics
D014613:Vaccines, Attenuated; D014765:Viral Vaccines